melanoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.
|
22535842 |
2012 |
Ischemia
|
0.200 |
Biomarker
|
phenotype |
RGD |
ZFM1/SF1 mRNA in rat and gerbil brain after global ischaemia.
|
10103072 |
1999 |
Multiple Endocrine Neoplasia Type 1
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The human SF1 gene is located on chromosome 11 close to the gene encoding Menin, recently identified as the gene responsible for multiple endocrine neoplasia-type 1 (MEN1).
|
9573336 |
1998 |
Multiple Endocrine Neoplasia Type 1
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
By differential screening of a cDNA library obtained from a GM-CSF-dependent human myeloid leukemia cell line (GF-D8), we identified two novel isoforms of the recently described ZNF162 gene, which is apparently linked to multiple endocrine neoplasia type 1.
|
9192847 |
1997 |
Multiple Endocrine Neoplasia Type 1
|
0.040 |
Biomarker
|
disease |
BEFREE |
Thus, our results indicate that ZFM1 is excluded as a candidate gene for MEN1.
|
9150722 |
1997 |
Multiple Endocrine Neoplasia Type 1
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that ZFM1 might be a candidate for mutations that cause MEN1.
|
7912130 |
1994 |
Adrenal gland hypofunction
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
In rare cases, sequence variants of the NR5A1/SF-1 gene may result in POI, or in various disorders of gonadal development (DGD) or adrenal insufficiency.
|
31831369 |
2019 |
Adrenal cortical hypofunction
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In rare cases, sequence variants of the NR5A1/SF-1 gene may result in POI, or in various disorders of gonadal development (DGD) or adrenal insufficiency.
|
31831369 |
2019 |
Adrenal gland hypofunction
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
A novel 8-bp microdeletion of the SF1 gene was identified in a 46,XY sex-reversed patient without adrenal insufficiency.
|
14689056 |
2004 |
Adrenal gland hypofunction
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
Four human SF1 gene mutations have been described to date: three (G35E, R92Q, R255L) were responsible for adrenal insufficiency associated with a gonadal dysgenesis in two 46, XY individuals, one (8 bp deletion in exon 6) resulted in gonadal dysgenesis without adrenal insufficiency.
|
15472171 |
2004 |
Adrenal cortical hypofunction
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Four human SF1 gene mutations have been described to date: three (G35E, R92Q, R255L) were responsible for adrenal insufficiency associated with a gonadal dysgenesis in two 46, XY individuals, one (8 bp deletion in exon 6) resulted in gonadal dysgenesis without adrenal insufficiency.
|
15472171 |
2004 |
Adrenal cortical hypofunction
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
A novel 8-bp microdeletion of the SF1 gene was identified in a 46,XY sex-reversed patient without adrenal insufficiency.
|
14689056 |
2004 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These data also present novel molecular mechanisms that may explain the loss of SF‑1 protein in ovarian tumors, and its potential role in ovarian carcinogenesis.
|
23291911 |
2013 |
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of SF1 was found to be correlated with the differentiation status of intestinal epithelial cells and inversely correlated with tumorigenesis.
|
17383426 |
2007 |
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The Splicing Factor-1 (SF-1), which is critical for smooth muscle cell proliferation and phenotype switch, was found to be elevated in collaterals of DM mice.
|
31284541 |
2019 |
Adenoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
DAX1 and SF1 protein expression were assessed in 104 ACTs from 34 children (25 clinically benign and 9 malignant) and 70 adults (40 adenomas and 30 carcinomas).
|
25985323 |
2015 |
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
DAX1 and SF1 protein expression were assessed in 104 ACTs from 34 children (25 clinically benign and 9 malignant) and 70 adults (40 adenomas and 30 carcinomas).
|
25985323 |
2015 |
Hypospadias
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of the SRD5A2, AR and SF-1 genes in 52 Chinese boys with hypospadias.
|
23729601 |
2013 |
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data also present novel molecular mechanisms that may explain the loss of SF‑1 protein in ovarian tumors, and its potential role in ovarian carcinogenesis.
|
23291911 |
2013 |
Penile hypospadias
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of the SRD5A2, AR and SF-1 genes in 52 Chinese boys with hypospadias.
|
23729601 |
2013 |
Adrenocortical carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, the SF-1 gene profile can be used to distinguish malignant from benign adrenocortical tumors, a finding that implicates SF-1 in the development of malignant adrenocortical carcinoma.
|
22427816 |
2012 |
Gonadal Dysgenesis, 46,XX
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Preserved fertility in a patient with a 46,XY disorder of sex development due to a new heterozygous mutation in the NR5A1/SF-1 gene: evidence of 46,XY and 46,XX gonadal dysgenesis phenotype variability in multiple members of an affected kindred.
|
22907560 |
2012 |
46, XY Disorders of Sex Development
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Three novel heterozygous SF-1 gene mutations affecting multiple members of two unrelated families with a history of 46,XY disorders of sex development (DSD) and 46,XX ovarian insufficiency are described.
|
20861607 |
2011 |
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
SF-1 protein expression was assessed in a cohort of 103 adrenocortical tumors from 36 children and 67 adults, whereas gene amplification was studied in 38 adrenocortical tumors (17 from children).
|
20080844 |
2010 |
Agenesis of corpus callosum
|
0.010 |
Biomarker
|
disease |
BEFREE |
SF-1 protein staining was detectable in 158 of 161 (98%) evaluable ACC samples including 49 (30%) with strong SF-1 staining and in all normal and benign steroidogenic tissues.
|
20660055 |
2010 |